Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study
source: American Society of Hematology
year: 2016
authors: nathan S Fishman, Joseph Kim, Daniel Lichy, Kathleen Vaughan, Stephen Yoon, Niral Sheth, James Ahad, Deepika Darbari, Katherine Chadwick, Hans Ackerman, Alexander M. Gorbach, James G. Taylor
summary/abstract:Background: Sickle cell anemia (SCA) is characterized by significant phenotypic variability. DOVE1 was a Phase 3, double-blind, randomized, parallel-group, placebo-controlled, multinational study that investigated the efficacy and safety of prasugrel, a P2Y12 adenosine diphosphate receptor antagonist, for reduction of vaso-occlusive crises (VOCs), a composite of painful crisis or acute chest syndrome, in 2- to <18-year-olds with SCA (age cohorts: 2 to <6 years, 6 to <12 years, and 12 to <18 years)
Methods: DOVE was conducted at 51 sites in 13 countries across 4 continents. A total of 341 subjects were randomized (prasugrel, n=171; placebo, n=170) and SCA genotypes (homozygous hemoglobin S; hemoglobin Sβ0 thalassemia) were included. Eligibility required >=2 VOCs in the prior year. Baseline clinical and laboratory characteristics and study endpoints were compared by region. Since no overall treatment effect was found, data provided reflect the combined 341 subjects (Americas, N=57; sub-Saharan Africa [SSA], N=148; North Africa/Middle East, N=110; Europe, N=26).
organization: Evelina London Children's Hospital; Guy's and St Thomas' Hospital NHS Trust, London; Azienda Ospedaliera - Università di Padova; King's College London; Boston Children’s Cancer and Blood Disorders Center; UCSF Benioff Children's Hospital Oakland; Kenya Medical Research Institute; Alexandria University; Eli Lilly and Company, Indianapolis; American University of Beirut Medical Centerread more
+myBinderRelated Content
-
Acute Chest Syndrome in Children with Sickle Cell DiseaseAcute chest syndrome (ACS) is a frequent...
-
How I Treat Acute and Persistent Sickle Cell PainSickle pain is the hallmark of sickle ce...
-
SPCI Launched the SCOT (Sickle Cell Omega-3 Treatment) Trial in the United States with an Investigator Meeting Held ...Sancilio Pharmaceuticals Company, Inc. (...
-
Sickle Cell Disease Management & Complications: Sophie Lanzkron MD of Johns HopkinsStuck on sickle cell disease? We hammer ...
-
Emmaus Life Sciences, Inc. to present results of phase 3 study of endariTM (L-glutamine oral powder) at 59th America...Emmaus will present results of a Phase 3...
-
Prolong Pharma’s Sanguinate Shows Promise in Reverting Shape of Red Blood Cells in SCDProlong Pharmaceuticals’ investigation...
-
Investigational Oral Inhibitor IMR-687 Shows Promising Results in Ongoing Phase 2 Clinical TrialImara’s investigational oral inhibitor...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.